A synthetic vaccine is a vaccine consisting mainly of synthetic peptides, carbohydrates, or antigens. They are usually considered to be safer than vaccines from bacterial cultures. Creating vaccines synthetically has the ability to increase the speed of production. This is especially important in the event of a pandemic.
During the H1N1 outbreak in 2009, vaccines only became available in large quantities after the peak of human infections. This was a learning experience for vaccination companies. Novartis Vaccine and Diagnostics, among other companies, developed a synthetic approach that very rapidly generates vaccine viruses from sequence data in order to be able to administer vaccinations early in the pandemic outbreak. Philip Dormatizer, the leader of viral vaccine research at Novartis, says they have "developed a way of chemically synthesizing virus genomes and growing them in tissue culture cells".[2]
Phase I data of UB-311, a synthetic peptide vaccine targeting amyloid beta, showed that the drug was able to generate antibodies to specific amyloid beta oligomers and fibrils with no decrease in antibody levels in patients of advanced age. Results from the Phase II trial are expected in the second half of 2018.[3][4]
Referencesedit
^Patarroyo, Manuel E. (May 30, 2007). "Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization". Vaccine. 25, 22 (22): 4487–4501. doi:10.1016/j.vaccine.2007.03.016. PMID 17403557.
^Young Rojahn, Susan (May 14, 2013). "Synthetic Biology Could Speed Flu Vaccine Production". MIT Technology Review.
^. Archived from the original on 2019-06-17. Retrieved 2017-11-09.{{cite web}}: CS1 maint: archived copy as title (link)[full citation needed]
^Wang, Chang Yi; Wang, Pei-Ning; Chiu, Ming-Jang; Finstad, Connie L; Lin, Feng; Lynn, Shugene; Tai, Yuan-Hung; De Fang, Xin; Zhao, Kesheng; Hung, Chung-Ho; Tseng, Yiting; Peng, Wen-Jiun; Wang, Jason; Yu, Chih-Chieh; Kuo, Be-Sheng; Frohna, Paul A (2017). "UB-311, a novel UBITh ® amyloid β peptide vaccine for mild Alzheimer's disease". Alzheimer's & Dementia: Translational Research & Clinical Interventions. 3 (2): 262–272. doi:10.1016/j.trci.2017.03.005. PMC5651432. PMID 29067332.
External linksedit
Web Health Centre: History of Vaccines
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.
synthetic, vaccine, synthetic, vaccine, vaccine, consisting, mainly, synthetic, peptides, carbohydrates, antigens, they, usually, considered, safer, than, vaccines, from, bacterial, cultures, creating, vaccines, synthetically, ability, increase, speed, product. A synthetic vaccine is a vaccine consisting mainly of synthetic peptides carbohydrates or antigens They are usually considered to be safer than vaccines from bacterial cultures Creating vaccines synthetically has the ability to increase the speed of production This is especially important in the event of a pandemic History editThe world s first synthetic vaccine was created in 1796 from diphtheria toxin by Louis Chedid scientist from the Pasteur Institute and Michael Sela from the Weizmann Institute citation needed In 1986 Manuel Elkin Patarroyo created the SPf66 the first version of a synthetic vaccine for Malaria 1 During the H1N1 outbreak in 2009 vaccines only became available in large quantities after the peak of human infections This was a learning experience for vaccination companies Novartis Vaccine and Diagnostics among other companies developed a synthetic approach that very rapidly generates vaccine viruses from sequence data in order to be able to administer vaccinations early in the pandemic outbreak Philip Dormatizer the leader of viral vaccine research at Novartis says they have developed a way of chemically synthesizing virus genomes and growing them in tissue culture cells 2 Phase I data of UB 311 a synthetic peptide vaccine targeting amyloid beta showed that the drug was able to generate antibodies to specific amyloid beta oligomers and fibrils with no decrease in antibody levels in patients of advanced age Results from the Phase II trial are expected in the second half of 2018 3 4 References edit Patarroyo Manuel E May 30 2007 Synthetic vaccine update Applying lessons learned from recent SPf66 malarial vaccine physicochemical structural and immunological characterization Vaccine 25 22 22 4487 4501 doi 10 1016 j vaccine 2007 03 016 PMID 17403557 Young Rojahn Susan May 14 2013 Synthetic Biology Could Speed Flu Vaccine Production MIT Technology Review Archived copy Archived from the original on 2019 06 17 Retrieved 2017 11 09 a href Template Cite web html title Template Cite web cite web a CS1 maint archived copy as title link full citation needed Wang Chang Yi Wang Pei Ning Chiu Ming Jang Finstad Connie L Lin Feng Lynn Shugene Tai Yuan Hung De Fang Xin Zhao Kesheng Hung Chung Ho Tseng Yiting Peng Wen Jiun Wang Jason Yu Chih Chieh Kuo Be Sheng Frohna Paul A 2017 UB 311 a novel UBITh amyloid b peptide vaccine for mild Alzheimer s disease Alzheimer s amp Dementia Translational Research amp Clinical Interventions 3 2 262 272 doi 10 1016 j trci 2017 03 005 PMC 5651432 PMID 29067332 External links editArticle on synthetic Hib vaccine CRISP Thesaurus entry on Synthetic Vaccines Web Health Centre History of Vaccines nbsp This article about vaccines or vaccination is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Synthetic vaccine amp oldid 1167153026, wikipedia, wiki, book, books, library,
